Published in Lancet on July 31, 2014
Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD) | NCT00000620
Effects of intensive glycaemic control on ischaemic heart disease. Lancet (2015) 1.03
A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease. Nat Commun (2015) 0.97
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA (2016) 0.96
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care (2016) 0.95
Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes: The 2015 Edwin Bierman Award Lecture. Diabetes (2016) 0.83
Glycaemic control, cardiovascular disease, and mortality in type 2 diabetes. Lancet (2014) 0.81
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus. J Diabetes Res (2015) 0.78
The EMPA-REG outcome study: critical appraisal and potential clinical implications. Cardiovasc Diabetol (2016) 0.77
Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin. Diabetes Obes Metab (2015) 0.77
Diabetes: Effects of strict glycaemic control on ischaemic heart disease. Nat Rev Cardiol (2014) 0.75
Diabetes Drugs and Cardiovascular Safety. Endocrinol Metab (Seoul) (2016) 0.75
Effects of intensive glycaemic control on ischaemic heart disease - Authors' reply. Lancet (2015) 0.75
Hypoglycemia in Diabetes Mellitus as a Coronary Artery Disease Risk Factor in Patients at Elevated Vascular Risk. J Clin Endocrinol Metab (2015) 0.75
Long-term insulin treatment restores cardioprotection induced by sufentanil postconditioning in diabetic rat heart. Exp Biol Med (Maywood) (2016) 0.75
A Link Between Hypoglycemia and Progression of Atherosclerosis in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care (2016) 0.75
Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin. Diabetes Metab Syndr Obes (2017) 0.75
Is glycemia control in Canadians with diabetes individualized? A cross-sectional observational study. BMJ Open Diabetes Res Care (2017) 0.75
The role of glycaemic and lipid risk factors in mediating the effect of BMI on coronary heart disease: a two-step, two-sample Mendelian randomisation study. Diabetologia (2017) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (2010) 11.55
Tutorial in biostatistics: competing risks and multi-state models. Stat Med (2007) 10.61
Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med (2011) 10.33
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Diagnosis and classification of diabetes mellitus. Diabetes Care (2013) 6.83
Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia (2009) 6.55
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.42
Counterpoint: Intensive glucose control and mortality in ACCORD--still looking for clues. Diabetes Care (2010) 1.20
Point: Intensive glycemic control and mortality in ACCORD--a chance finding? Diabetes Care (2010) 1.13
Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study. J Am Coll Cardiol (2012) 1.06
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.14
Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.49
Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.10
Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 2.98
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int (2011) 1.91
The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol (2007) 1.85
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol (2007) 1.47
A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology (2003) 1.01
Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int (2014) 0.99
Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care (2016) 0.95
Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. Am J Cardiol (2007) 0.94
Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care (2012) 0.91
Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care (2013) 0.87
Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. Am J Hypertens (2015) 0.78
Effects of intensive glycaemic control on ischaemic heart disease - Authors' reply. Lancet (2015) 0.75
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. Am J Nephrol (2016) 0.75
Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. Am J Nephrol (2016) 0.75